Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month
Piramal and NP2 are set to complete the drug development phase of the generic cancer drug cyclophosphamide this October. The development and manufacturing activities are being conducted at Piramal's dedicated sterile injectable facility in Lexington, Kentucky. This partnership addresses ongoing cyclophosphamide shortages and supply chain risks, safeguarding...
Phrontline Biopharma Doses First Patient in Global Phase I/II Trial of TJ102, an FRα × CDH6 Bispecific Dual-Payload ADC
First clinical program built on Phrontline's DLP1 branched dual-payload linker platform HANGZHOU, China and SHANGHAI, Sept. 30, 2026 /PRNewswire/ -- Phrontline Biopharma, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), today announced that the first patient has been dosed in its global, first-in-human Phase I/II study of TJ102, an investigational FRα (FOLR1) × CDH6 bispecific dual-payload ADC,...
The 94th CMEF, the World’s Leading Medical Device Industry Event, Set to Open in Beijing Oct. 21-24
BEIJING, Sept. 30, 2026 /PRNewswire/ -- The 94th China International Medical Equipment Fair (CMEF) and concurrent events—including ICMD, covering medical device design and manufacturing; CRS, focusing on rehabilitation and assistive technology; CECN, dedicated to elderly care and nursing; and Healthy Lifestyle—will take place October 21–24 at the Capital International Exhibition & Convention Center in Beijing. Organized by Reed...
Yuyu Pharma Brings Ari’s Purrfect to Amazon Accelerate 2026
Korean pharmaceutical company explores Amazon AI and seller tools to grow its U.S. feline-health brand SEOUL, South Korea, Sept. 30, 2026 /PRNewswire/ -- Robert Wonsang Yu, CEO of Yuyu Pharma (KRX: 000220), attended Amazon Accelerate 2026 in Seattle from September 22 to 24 to explore how Amazon's newest AI, consumer data,...
Joint Commission International Honors Healthcare Organizations and National Health Authorities with Inaugural Global Patient Safety Awards
OAK BROOK TERRACE, Ill., Sept. 30, 2026 /PRNewswire/ -- Joint Commission International (JCI) recognized the winners of the inaugural Global Patient Safety Awards today at UNIFY 2026™: Convening for Quality, Joint Commission's annual, flagship conference that brings together global healthcare leaders for two days of discussions focused on the future of healthcare...
Zhendong Pharmaceutical Announces Publication of Phase IIb Study of Investigational Vaginal Lactobacillus Capsule in the National Medical Journal of China
BEIJING, Sept. 30, 2026 /PRNewswire/ -- Zhendong Pharmaceutical announced that results from a multicenter, randomized, double-blind, placebo-controlled Phase IIb study evaluating its investigational Live Double Combined Lactobacillus Capsule for Vaginal Use for the treatment of bacterial vaginosis (BV) were published in the National Medical Journal of China. The eight-center study randomized 66 patients in an approximately 2:1 ratio...
POMDOCTOR LIMITED Accelerates AI-Enabled Chronic Disease Management and RWD Commercialization
GUANGZHOU, China, Sept. 30, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today provided an update on the continued progress in the development and commercialization of its AI-enabled chronic disease management ecosystem, including further optimization of its proprietary AI chronic disease management system, expanded real-world...
Zhongchao Inc. Announces 1-for-2 Share Consolidation
SHANGHAI, Sept. 30, 2026 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that the Company will effectuate a 1-for-2 share consolidation of the Company's ordinary shares of US$0.744 par value each (the "Share Consolidation"). Beginning with the opening of...
EASD 2026 | Ecnoglutide Demonstrates Favorable Safety Profile in Adolescents with Obesity
HANGZHOU, China, Sept. 30, 2026 /PRNewswire/ -- At the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind") today announced that its Phase 1b randomized, double-blind, placebo-controlled study of ecnoglutide, the world's first cAMP-biased GLP-1 receptor agonist, conducted in Chinese adolescents with obesity, was accepted as a Late-Breaking...
RSMC Highlights Diverse Families Ahead of Taiwan Pride as Same-Sex Couple Shares Fertility Journey
SHENZHEN, SHANGHAI and TAIPEI, Sept. 30, 2026 /PRNewswire/ -- As Taiwan's Pride season approaches in late October, diverse families and fertility choices are once again drawing public attention. For LGBTQ+ families considering parenthood, decisions may involve a range of factors, from reproductive options and medical considerations to family planning. As information about reproductive medicine overseas becomes increasingly accessible, some...
